Long-acting insulin formulationsAn aqueous pharmaceutical formulation with pH between 3.4 and 4.6 comprising insulin glargine, wherein the concentration of insulin glargine is 200-500 U / mL, which is equimolar to 200-500 IU of human insulin.BECKER, REINHARDFRICK, ANNKE...
Rapid-acting insulin formulations available in the United States include lispro, aspart, and glulisine, created through amino acid substitutions in the insulin peptide chains. These formulations achieve their desired effect when administered subcutaneously, because intravenous injection leads to a delay in...
(2000). Unlike the conventional long-acting insulin formulations (isophane insulin or insulin zinc suspension ultralente), there is no peak in the plasma concentration of insulinLepore et al (2000). Therefore, insulin glargine may be used to produce a basal insulin concentration and can be used...
The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum...
Rapid acting and long acting insulin combination formulations 发明人: STEINER SOLOMON S.;POHL RODERIKE 申请人: 申请日期: 2007-04-02 申请公布日期: 2010-05-11 代理机构: 代理人: 地址: 摘要: A combined rapid acting-long acting insulin formulation has been developed in which the pH of th...
To compare hypoglycemia event rates in patients initiated on long-acting insulin analog (glargine) or intermediate-acting insulin (NPH) and to analyze the ... Michael,F,Bullano,... - 《Current Medical Research & Opinion》 被引量: 104发表: 2005年 Insulin formulations - A review Human biosynth...
Long-acting Formulations: Several approaches have been taken to develop long-acting forms of GH and to extend the half-life of GH-releasing factor. Each of these preparations has been tested in experimental animal models and found to extend the half-life of GH and GH-releasing hormone (GHRH)...
The major advantage is that the insulin used is not modified by Medusa. A phase I clinical trial has demonstrated that LABI is able to release human insulin over a period of time much longer than with traditional long-acting insulin formulations. Such a capability makes LABI a very promising ...
Most pharmaceuticals are given using short-acting formulations that require frequent administration, which can negatively affect patient compliance and increase failure risks associated with inconsistent use. By contrast, long-acting release formulations can achieve sustained release of drugs for weeks, months...
However, the impact of different formulations and the duration of treatment on insulin's efficacy and the cellular processes targeted by the treatment remain unclear. Here, we tested whether intranasal insulin aspart, a short-acting insulin formulation, could alleviate memory decline as...